Cancer, obesity, diabetes, and antidiabetic drugs: Is the fog clearing?

Nature Reviews Clinical Oncology

Volumn 14, Issue 2, 2017, Pages 85-99

  Klil Drori, Adi J ^a,b   Azoulay, Laurent ^a,b   Pollak, Michael N ^b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANTIDIABETIC AGENT; BEVACIZUMAB; CYTOKINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ESTROGEN; EVEROLIMUS; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOCORTICOID; INSULIN; INSULIN GLARGINE; INSULIN RECEPTOR; LEPTIN; METFORMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIOGLITAZONE; RAPAMYCIN DERIVATIVE; SOMATOMEDIN; SOMATOMEDIN C RECEPTOR; SULFONYLUREA DERIVATIVE; TEMSIROLIMUS; ANTIANDROGEN; ANTINEOPLASTIC AGENT; RAPAMYCIN;

ANDROGEN DEPRIVATION THERAPY; BODY MASS; CALORIC INTAKE; CALORIC RESTRICTION; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVOR; CHRONIC INFLAMMATION; DIABETES MELLITUS; ENDOMETRIUM CANCER; GALLBLADDER CANCER; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN TREATMENT; INTRACELLULAR SIGNALING; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CANCER; MALIGNANT NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY CANCER; PANCREAS CANCER; PREVALENCE; RECURRENCE FREE SURVIVAL; REVIEW; RISK REDUCTION; WEIGHT GAIN; WEIGHT REDUCTION; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLOBAL HEALTH; INCIDENCE; METABOLISM; NEOPLASMS; PROGNOSIS; RISK FACTOR; SIGNAL TRANSDUCTION; SURVIVOR;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; DIABETES MELLITUS, TYPE 2; GLOBAL HEALTH; GLUCOCORTICOIDS; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; NEOPLASMS; OBESITY; PREVALENCE; PROGNOSIS; RISK FACTORS; SIGNAL TRANSDUCTION; SIROLIMUS; SURVIVORS;

EID: 84981163280     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2016.120     Document Type: Review

References (201)

1. Tuffier, T. Diabete et neoplasmes. Archives generales de medecine 7, 129-140 (1888
2. Bapat S. P., et al. Depletion of fat-resident Treg cells prevents age-Associated insulin resistance. Nature 528, 137-141 (2015
3. Langenberg, C., et al. Long-Term risk of incident type 2 diabetes and measures of overall and regional obesity: the EPIC-InterAct case-cohort study. PLoS Med. 9, e1001230 (2012
4. Ng, M., et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980 2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384, 766-781 (2014
5. Singh, G. M., et al. The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis. PLoS ONE 8, e65174 (2013
6. Berrington de Gonzalez, A., et al. Body-mass index and mortality among 1.46 million white adults. N. Engl. J. Med. 363, 2211-2219 (2010
7. authors listed]. Diabetes Fact Sheet. WHO http://www.who.int/mediacentre/factsheets/fs312/en/(2015
8. Di Angelantonio E., et al. Association of cardiometabolic multimorbidity with mortality. JAMA 314, 52-60 (2015
9. Murray C. J., et al. Global, regional, and national disability-Adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990 2013: quantifying the epidemiological transition. Lancet http://dx.doi.org/10.1016/s0140-6736(15)61340-x 2015
10. Torre, L. A., et al. Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87-108 (2015
11. Guariguata, L., et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res. Clin. Pract. 103, 137-149 (2014
12. Ogden C. L., Carroll, M. D., Fryar, C. D., & Flegal, K. M. Prevalence of obesity among adults and youth: United States, 2011-2014. NCHS Data Brief 1-8 2015
13. Youlden, D. R., et al. The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol. 36, 237-248 (2012
14. Arnold, M., et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 16, 36-46 (2015
15. Wells, J. C., Coward, W. A., Cole, T. J., & Davies, P. S. The contribution of fat and fat-free tissue to body mass index in contemporary children and the reference child. Int. J. Obes Relat. Metab. Disord. 26, 1323-1328 (2002
16. Kaaks, R., & Kühn, T. Epidemiology: obesity and cancer-The evidence is fattening up. Nat. Rev. Endocrinol. 10, 644-645 (2014
17. Keum, N., et al. Adult weight gain and adiposity-related cancers: a dose-response meta-Analysis of prospective observational studies. J. Natl Cancer Inst. 107, http://dx.doi.org/10.1093/jnci/djv088 (2015
18. Renehan, A. G., Tyson, M., Egger, M., Heller, R. F., & Zwahlen, M. Body-mass index and incidence of cancer: a systematic review and meta-Analysis of prospective observational studies. Lancet 371, 569-578 (2008
19. World Cancer Research Fund and the American Institute for Cancer Research. Continuous update project report: diet, nutrition, physical activity and liver cancer. http://wcrf.org/sites/default/files/Liver-Cancer-2015-Report.pdf (2015
20. World Cancer Research Fund and the American Institute for Cancer Research. Continuous update project report. Food, nutrition, physical activity, and the prevention of breast cancer. http://wcrf.org/sites/default/files/Breast-Cancer-2010-Report.pdf (2015
21. World Cancer Research Fund and the American Institute for Cancer Research. Continuous update project report: diet, nutrition, physical activity, and prostate cancer. http://wcrf.org/sites/default/files/Prostate-Cancer-2014-Report.pdf (2015
22. Lerro, C. C., McGlynn, K. A., & Cook, M. B. A systematic review and meta-Analysis of the relationship between body size and testicular cancer. Br. J. Cancer 103, 1467-1474 (2010
23. Yang, Y., et al. Obesity and incidence of lung cancer: a meta-Analysis. Int. J. Cancer 132, 1162-1169 (2013
24. Song M., et al. Trajectory of body shape across the lifespan and cancer risk. Int. J. Cancer http://dx.doi.org/10.1002/ijc.29981 2015
25. Neuhouser, M. L., et al. Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the women's health initiative randomized clinical trials. JAMA Oncol. 1, 611-621 (2015
26. Reeves, G. K., et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 335, 1134 (2007
27. Adams, T. D., et al. Long-Term mortality after gastric bypass surgery. N. Engl. J. Med. 357, 753-761 (2007
28. Sjostrom, L., et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 10, 653-662 (2009
29. Douglas, I. J., Bhaskaran, K., Batterham, R. L., & Smeeth, L. Bariatric surgery in the United Kingdom: a cohort study of weight loss and clinical outcomes in routine clinical care. PLoS Med. 12, e1001925 (2015
30. Eliassen, A. H., Colditz, G. A., Rosner, B., Willett, W. C., & Hankinson, S. E. Adult weight change and risk of postmenopausal breast cancer. JAMA 296, 193-201 (2006
31. Parker, E. D., & Folsom, A. R. Intentional weight loss and incidence of obesity-related cancers: the Iowa Women's Health Study. Int. J. Obes Relat. Metab. Disord. 27, 1447-1452 (2003
32. Tsilidis, K. K., Kasimis, J. C., Lopez, D. S., Ntzani, E. E., & Ioannidis, J. P. Type 2 diabetes and cancer: umbrella review of meta-Analyses of observational studies. BMJ 350, g7607 (2015
33. Carstensen, B., Witte, D. R., & Friis, S. Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia 55, 948-958 (2012
34. Geier, A. S., et al. Cancer detection rates following enrolment in a disease management programme for type 2 diabetes. Diabetologia 56, 1944-1948 (2013
35. Bansal, D., Bhansali, A., Kapil, G., Undela, K., & Tiwari, P. Type 2 diabetes and risk of prostate cancer: a meta-Analysis of observational studies. Prostate Cancer Prostat. Dis. 16, 151-158 (2013
36. Tseng, C. H. Diabetes and risk of prostate cancer: a study using the National Health Insurance. Diabetes Care 34, 616-621 (2011
37. Dhindsa, S., et al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J. Clin. Endocrinol. Metab. 89, 5462-5468 (2004
38. Freedland, S. J., & Aronson, W. J. Obesity and prostate cancer. Urology 65, 433-439 (2005
39. Ma, J., et al. Prediagnostic body-mass index, plasma C peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-Term survival analysis. Lancet Oncol. 9, 1039-1047 (2008
40. Gandini, S., et al. Metformin and cancer risk and mortality: a systematic review and meta-Analysis taking into account biases and confounders. Cancer Prev. Res. (Phila.) 7, 867-885 (2014
41. Wu, L., Zhu, J., Prokop, L. J., & Murad, M. H. Pharmacologic therapy of diabetes and overall cancer risk and mortality: a meta-Analysis of 265 studies. Sci. Rep. 5, 10147 (2015
42. Evans, J. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. Metformin and reduced risk of cancer in diabetic patients. BMJ 330, 1304-1305 (2005
43. Colhoun, H. M., & Group, S. E. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52, 1755-1765 (2009
44. Bronsveld, H. K., et al. Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-Analysis of in vitro, animal and human evidence. Breast Cancer Res. 17, 100 (2015
45. Kowall, B., Stang, A., Rathmann, W., & Kostev, K. No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK. Pharmacoepidemiol. Drug Saf. 24, 865-874 (2015
46. Suissa, S., & Azoulay, L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 35, 2665-2673 (2012
47. Pocock, S. J., & Smeeth, L. Insulin glargine and malignancy: an unwarranted alarm. Lancet 374, 511-513 (2009
48. Garber, A. J., et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr. Pract. 21, 438-447 (2015
49. Pollak, M. Overcoming drug development bottlenecks with repurposing: repurposing biguanides to target energy metabolism for cancer treatment. Nat. Med. 20, 591-593 (2014
50. Pollak, M. N. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov. 2, 778-790 (2012
51. Decensi, A., et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-Analysis. Cancer Prev. Res. (Phila.) 3, 1451-1461 (2010
52. Libby, G., et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32, 1620-1625 (2009
53. Noto, H., Goto, A., Tsujimoto, T., & Noda, M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-Analysis. PLoS ONE 7, e33411 (2012
54. Mamtani, R., et al. Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas. Diabetes Care 37, 1910-1917 (2014
55. Tsilidis, K. K., et al. Metformin does not affect cancer risk: a cohort study in the UK Clinical Practice Research Datalink analyzed like an intention-To treat trial. Diabetes Care 37, 2522-2532 (2014
56. Higurashi T., et al. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol. http://dx.doi.org/10.1016/s1470-2045(15)00565-3 2016
57. Currie, C. J., Poole, C. D., & Gale, E. A. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52, 1766-1777 (2009
58. Hemkens, L. G., et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52, 1732-1744 (2009
59. Jonasson, J. M., et al. Insulin glargine use and short-Term incidence of malignancies a population-based follow up study in Sweden. Diabetologia 52, 1745-1754 (2009
60. Mayer, D., Shukla, A., & Enzmann, H. Proliferative effects of insulin analogues on mammary epithelial cells. Arch. Physiol. Biochem. 114, 38-44 (2008
61. Wu J. W., Filion, K. B., Azoulay, L., Doll, M. K., & Suissa, S. The effect of long-Acting insulin analogs on the risk of cancer: a systematic review of observational studies. Diabetes Care http://dx.doi.org/10.2337/dc15-1816 2016
62. Proks, P., Reimann, F., Green, N., Gribble, F., & Ashcroft, F. Sulfonylurea stimulation of insulin secretion. Diabetes 51 (Suppl. 3), S368-S376 (2002
63. Pollak, M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat. Rev. Cancer 12, 159-169 (2012
64. Chang, C. H., Lin, J. W., Wu, L. C., Lai, M. S., & Chuang, L. M. Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 97, E1170-1175 (2012
65. Kowall, B., Rathmann, W., & Kostev, K. Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis. Diabetes Care 38, 59-65 (2015
66. Tuccori, M., Wu, J. W., Yin, H., Majdan, A., & Azoulay, L. The use of glyburide compared with other sulfonylureas and the risk of cancer in patients with type 2 diabetes. Diabetes Care 38, 2083-2089 (2015
67. Loke, Y. K., & Mattishent, K. Bladder cancer: pioglitazone-when is a prescription drug safe? Nat. Rev. Urol. 12, 655-656 (2015
68. Dormandy, J. A., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366, 1279-1289 (2005
69. Lewis, J. D., et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 34, 916-922 (2011
70. Azoulay, L., et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 344, e3645 (2012
71. U.S. Food and Drug Administration. FDA Drug Safety Communication: update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer. http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm (2012
72. Levin, D., et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 58, 493-504 (2015
73. Lewis, J. D., et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA 314, 265-277 (2015
74. Faillie J. L., & Hillaire-Buys, D. Examples of how the pharmaceutical industries distort the evidence of drug safety: the case of pioglitazone and the bladder cancer issue. Pharmacoepidemiol. Drug Saf. http://dx.doi.org/10.1002/pds.3925 2015
75. Tuccori, M., et al. Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ 352, i1541 (2016
76. Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide 1 based therapies. Gastroenterology 141, 150-156 (2011
77. Raschi, E., Piccinni, C., Poluzzi, E., Marchesini, G., & De Ponti, F. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetol. 50, 569-577 (2013
78. Azoulay, L. Incretin-based drugs and adverse pancreatic events: almost a decade later and uncertainty remains. Diabetes Care 38, 951-953 (2015
79. Gokhale, M., et al. Dipeptidyl-peptidase 4 inhibitors and pancreatic cancer: a cohort study. Diabetes, Obes. Metabolism 16, 1247-1256 (2014
80. Tseng, C. H. Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes. Eur. J. Clin. Invest. 46, 70-79 (2016
81. Green, J. B., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 373, 232-242 (2015
82. Egan, A. G., et al. Pancreatic safety of incretin-based drugs-FDA and EMA assessment. N. Engl. J. Med. 370, 794-797 (2014
83. Waser, B., Beetschen, K., Pellegata, N. S., & Reubi, J. C. Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy. Neuroendocrinology 94, 291-301 (2011
84. Rosol, T. J. On target effects of GLP 1 receptor agonists on thyroid C cells in rats and mice. Toxicol. Pathol. 41, 303-309 (2013
85. Drab S. R. Glucagon-like peptide 1 receptor agonists for type 2 diabetes: a clinical update of safety and efficacy. Curr. Diabetes Rev. http://dx.doi.org/10.2174/1573399812666151223093841 2015
86. Koehler, J. A., et al. GLP 1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7. Cell. Metab. 21, 379-391 (2015
87. Argiles, J. M., Busquets, S., Stemmler, B., & Lopez-Soriano, F. J. Cancer cachexia: understanding the molecular basis. Nat. Rev. Cancer 14, 754-762 (2014
88. Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N. Engl. J. Med. 348, 1625-1638 (2003
89. Calle, E. E., & Terrell, D. D. Utility of the National Death Index for ascertainment of mortality among cancer prevention study II participants. Am. J. Epidemiol. 137, 235-241 (1993
90. Chan, D. S., et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-Analysis of 82 follow up studies. Ann. Oncol. 25, 1901-1914 (2014
91. Copson, E. R., et al. Obesity and the outcome of young breast cancer patients in the UK: the POSH study. Ann. Oncol. 26, 101-112 (2015
92. Playdon, M. C., et al. weight gain after breast cancer diagnosis and all-cause mortality: systematic review and meta-Analysis. J. Natl Cancer Inst. 107, djv275 (2015
93. Pettersson, A., et al. Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. J. Natl Cancer Inst. 105, 1881-1890 (2013
94. Goodwin, P. J., et al. Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial. J. Clin. Oncol. 32, 2231-2239 (2014
95. Rossi, E. L., et al. Obesity-Associated alterations in inflammation, epigenetics, and mammary tumor growth persist in formerly obese mice. Cancer Prev. Res. (Phila.) 9, 339-348 (2016
96. Widschwendter, P., et al. The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial. Breast Cancer Res. 17, 129 (2015
97. Nagle, C. M., et al. Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. Br. J. Cancer 113, 817-826 (2015
98. Hakimi, A. A., et al. An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. J. Natl Cancer Inst. 105, 1862-1870 (2013
99. Lavie, C. J., McAuley, P. A., Church, T. S., Milani, R. V., & Blair, S. N. Obesity and cardiovascular diseases: implications regarding fitness, fatness, and severity in the obesity paradox. J. Am. College Cardiol. 63, 1345-1354 (2014
100. Tseng, C. H. Obesity paradox: differential effects on cancer and noncancer mortality in patients with type 2 diabetes mellitus. Atherosclerosis 226, 186-192 (2013
101. Seshasai, S. R., et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N. Engl. J. Med. 364, 829-841 (2011
102. Stein, K. B., et al. Colorectal cancer outcomes, recurrence, and complications in persons with and without diabetes mellitus: a systematic review and meta-Analysis. Dig. Dis. Sci. 55, 1839-1851 (2010
103. Snyder, C. F., et al. Does pre-existing diabetes affect prostate cancer prognosis? A systematic review. Prostate Cancer Prostat. Dis. 13, 58-64 (2010
104. Bensimon, L., Yin, H., Suissa, S., Pollak, M. N., & Azoulay, L. Type 2 diabetes and the risk of mortality among patients with prostate cancer. Cancer Causes Control 25, 329-338 (2014
105. Haggstrom, C., et al. Prostate cancer, prostate cancer death, and death from other causes, among men with metabolic aberrations. Epidemiology 25, 823-828 (2014
106. Peairs, K. S., et al. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-Analysis. J. Clin. Oncol. 29, 40-46 (2011
107. Luo, J., et al. Pre-existing diabetes and breast cancer prognosis among elderly women. Br. J. Cancer 113, 827-832 (2015
108. Wu, A. H., et al. Diabetes and other comorbidities in breast cancer survival by race/ethnicity: the California Breast Cancer Survivorship Consortium (CBCSC). Cancer Epidemiol. Biomarkers Prev. 24, 361-368 (2015
109. Fleming, S. T., Rastogi, A., Dmitrienko, A., & Johnson, K. D. A comprehensive prognostic index to predict survival based on multiple comorbidities: a focus on breast cancer. Med. Care 37, 601-614 (1999
110. Srokowski, T. P., Fang, S., Hortobagyi, G. N., & Giordano, S. H. Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. J. Clin. Oncol. 27, 2170-2176 (2009
111. Margel, D., et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J. Clin. Oncol. 31, 3069-3075 (2013
112. Bensimon, L., Yin, H., Suissa, S., Pollak, M. N., & Azoulay, L. The use of metformin in patients with prostate cancer and the risk of death. Cancer Epidemiol. Biomarkers Prev. 23, 2111-2118 (2014
113. Stopsack, K. H., Ziehr, D. R., Rider, J. R., & Giovannucci, E. L. Metformin and prostate cancer mortality: a meta-Analysis. Cancer Causes Control http://dx.doi.org/10.1007/s10552-015-0687-0 (2015
114. Zhang Z. J., & Li, S. The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-Analysis. Diabetes Obes. Metab. 16, 707-710 (2014
115. He, X., et al. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann. Oncol. 23, 1771-1780 (2012
116. Romero, I. L., et al. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstetr. Gynecol. 119, 61-67 (2012
117. Liu, Z., et al. High sensitivity of an Ha RAS transgenic model of superficial bladder cancer to metformin is associated with approximately 240 fold higher drug concentration in urine than serum. Mol. Cancer Ther. 15, 430-438 (2016
118. Peng, M., et al. High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model. Oncotarget http://dx.doi.org/10.18632/oncotarget.6933 (2016
119. Nayan M., et al. The effect of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Urol. Oncol. 33, 386. e387-e313 (2015
120. US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/results?term=%22 cancer%22+AND+%22metformin%22+AND+ %22treating%22&Search=Search (2015
121. DeCensi A., et al. Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. Breast Cancer Res. Treat. 148, 81-90 (2014
122. Lord, S. R., et al. Neoadjuvant window studies of metformin and biomarker development for drugs targeting cancer metabolism. J. Natl Cancer Inst. Monogr. 2015, 81-86 (2015
123. Hadad, S. M., et al. Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial. Breast Cancer Res. Treat. 150, 149-155 (2015
124. Kordes, S., et al. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 16, 839-847 (2015
125. Reni, M., et al. (Ir)relevance of metformin treatment in patients with metastatic pancreatic cancer: an open-label, randomized phase 2 trial. Clin. Cancer Res. http://dx.doi.org/10.1158/1078-0432.ccr-15-1722 (2015
126. Goodwin, P. J., et al. Effect of metformin versus placebo on and metabolic factors in NCIC CTG MA.32. J. Natl Cancer Inst. 107, http://dx.doi.org/10.1093/jnci/djv006 (2015
127. Goodwin, P. J., et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J. Clin. Oncol. 20, 42-51 (2002
128. Vissers, P. A., et al. The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes. Breast Cancer Res. Treatment 150, 427-437 (2015
129. Gallagher, E. J., & LeRoith, D. Obesity and diabetes: the increased risk of cancer and cancer-related mortality. Physiol. Rev. 95, 727-748 (2015
130. Pollak, M. Do cancer cells care if their host is hungry? Cell. Metabolism 9, 401-403 (2009
131. Allott, E. H., & Hursting, S. D. Obesity and cancer: mechanistic insights from transdisciplinary studies. Endocr. Relat. Cancer 22, R365-R386 (2015
132. Iyengar, N. M., Hudis, C. A., & Dannenberg, A. J. Obesity and cancer: local and systemic mechanisms. Annu. Rev. Med. 66, 297-309 (2015
133. Renehan, A. G., Zwahlen, M., & Egger, M. Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat. Rev. Cancer 15, 484-498 (2015
134. Tannenbaum, A., & Silverstone, H. The influence of the degree of caloric restriction on the formation of skin tumors and hepatomas in mice. Cancer Res. 9, 724-727 (1949
135. Algire, C., Amrein, L., Zakikhani, M., Panasci, L., & Pollak, M. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr. Relat. Cancer 17, 351-360 (2010
136. Murphy, N., et al. A nested case-control study of metabolically defined body size phenotypes and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). PLoS. Med. 13, e1001988 (2016
137. Wolpin, B. M., et al. Hyperglycaemia, insulin resistance, impaired pancreatic beta-cell function, and risk of pancreatic cancer. J. Natl Cancer Inst. 105, 1027-1035 (2013
138. Pal, A., et al. PTEN mutations as a cause of constitutive insulin sensitivity and obesity. N. Engl. J. Med. 367, 1002-1011 (2012
139. Ortega-Molina, A., et al. Pharmacological inhibition of PI3K reduces adiposity and metabolic syndrome in obese mice and rhesus monkeys. Cell. Metabolism 21, 558-570 (2015
140. Belfiore, A., Frasca, F., Pandini, G., Sciacca, L., & Vigneri, R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr. Rev. 30, 586-623 (2009
141. Chan, J. M., et al. Plasma insulin-like growth factor I and prostate cancer risk: a prospective study. Science 279, 563-566 (1998
142. Travis, R. C., et al. A meta-Analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk. Cancer Res. 76, 2288-2300 (2016
143. Thissen, J. P., Underwood, L. E., & Ketelslegers, J. M. Regulation of insulin-like growth factor I in starvation and injury. Nutr. Rev. 57, 167-176 (1999
144. Baxter, R. C. IGF binding proteins in cancer: mechanistic and clinical insights. Nat. Rev. Cancer 14, 329-341 (2014
145. Key, T. J., et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J. Natl Cancer Inst. 95, 1218-1226 (2003
146. Hofmann, J. N., et al. A prospective study of circulating adipokine levels and risk of multiple myeloma. Blood 120, 4418-4420 (2012
147. Inamura, K., et al. Prediagnosis plasma adiponectin in relation to colorectal cancer risk according to KRAS mutation status. J. Natl Cancer Inst. 108, http://dx.doi.org/10.1093/jnci/djv363 (2016
148. Bao, Y., et al. A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. J. Natl Cancer Inst. 105, 95-103 (2013
149. Hofmann, J. N., et al. Low levels of circulating adiponectin are associated with multiple myeloma risk in overweight and obese individuals. Cancer Res. 76, 1935-1941 (2016
150. Arita, Y., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257, 79-83 (1999
151. Zakikhani, M., Dowling, R. J., Sonenberg, N., & Pollak, M. N. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-Activated protein kinase. Cancer Prev. Res. (Phila.) 1, 369-375 (2008
152. Vansaun, M. N. Molecular pathways: adiponectin and leptin signaling in cancer. Clin. Cancer Res. 19, 1926-1932 (2013
153. Font-Burgada, J., Sun, B., & Karin, M. Obesity and cancer: the oil that feeds the flame. Cell. Metabolism 23, 48-62 (2016
154. Iyengar N. M., et al. Systemic correlates of white adipose tissue inflammation in early-stage breast cancer. Clin. Cancer Res. http://dx.doi.org/10.1158/1078-0432.ccr-15-2239 2015
155. Zhang, D., et al. Neutrophil ageing is regulated by the microbiome. Nature 525, 528-532 (2015
156. Ridaura, V. K., et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 341, 1241214 (2013
157. Ussar, S., et al. Interactions between gut microbiota, host genetics and diet modulate the predisposition to obesity and metabolic syndrome. Cell. Metabolism 22, 516-530 (2015
158. Moiseeva, O., et al. Metformin inhibits the senescence-Associated secretory phenotype by interfering with IKK/NF ?B activation. Aging Cell 12, 489-498 (2013
159. Lee, S. Y., et al. Metformin ameliorates inflammatory bowel disease by suppression of the STAT3 signaling pathway and regulation of the between Th17/Treg balance. PLoS ONE 10, e0135858 (2015
160. Forslund, K., et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528, 262-266 (2015
161. Haywood, A., et al. Corticosteroids for the management of cancer-related pain in adults. Cochrane Database Syst. Rev. 4, CD010756 (2015
162. Ferris, H. A., & Kahn, C. R. New mechanisms of glucocorticoid-induced insulin resistance: make no bones about it. J. Clin. Invest. 122, 3854-3857 (2012
163. Mazziotti, G., Gazzaruso, C., & Giustina, A. Diabetes in Cushing syndrome: basic and clinical aspects. Trends Endocrinol. Metabolism 22, 499-506 (2011
164. Fong, A. C., & Cheung, N. W. The high incidence of steroid-induced hyperglycaemia in hospital. Diabetes Res. Clin. Pract. 99, 277-280 (2013
165. Ariaans, G., et al. Cancer-drug induced insulin resistance: innocent bystander or unusual suspect. Cancer Treat. Rev. 41, 376-384 (2015
166. Sonabend, R. Y., et al. Hyperglycaemia during induction therapy is associated with poorer survival in children with acute lymphocytic leukemia. J. Pediatr. 155, 73-78 (2009
167. Chow, E. J., et al. Glucocorticoids and insulin resistance in children with acute lymphoblastic leukemia. Pediatr. Blood Cancer 60, 621-626 (2013
168. Dool, C. J., et al. IGF1/insulin receptor kinase inhibition by BMS 536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer. Endocr. Relat. Cancer 18, 699-709 (2011
169. Gosmanov, A. R., Goorha, S., Stelts, S., Peng, L., & Umpierrez, G. E. Management of hyperglycaemia in diabetic patients with hematologic malignancies during dexamethasone therapy. Endocr. Pract. 19, 231-235 (2013
170. Yu, I. C., Lin, H. Y., Sparks, J. D., Yeh, S., & Chang, C. Androgen receptor roles in insulin resistance and obesity in males: the linkage of androgen-deprivation therapy to metabolic syndrome. Diabetes 63, 3180-3188 (2014
171. Laaksonen, D. E., et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-Aged men. Diabetes Care 27, 1036-1041 (2004
172. Bosco, C., Crawley, D., Adolfsson, J., Rudman, S., & Van Hemelrijck, M. Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-Analysis. PLoS ONE 10, e0117344 (2015
173. Keating, N. L., Liu, P. H., O'Malley, A. J., Freedland, S. J., & Smith, M. R. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur. Urol. 65, 816-824 (2014
174. Keating, N. L., O'Malley, A. J., Freedland, S. J., & Smith, M. R. Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur. Urol. 64, 159-166 (2013
175. Lubik, A. A., et al. Insulin increases de novo steroidogenesis in prostate cancer cells. Cancer Res. 71, 5754-5764 (2011
176. Gunter, J. H., Lubik, A. A., McKenzie, I., Pollak, M., & Nelson, C. C. The interactions between insulin and androgens in progression to castrate-resistant prostate cancer. Adv. Urol. 2012, 248607 (2012
177. Cully, M., You, H., Levine, A. J., & Mak, T. W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 6, 184-192 (2006
178. Yap, T. A., Bjerke, L., Clarke, P. A., & Workman, P. Drugging PI3K in cancer: refining targets and therapeutic strategies. Curr. Opin. Pharmacol. 23, 98-107 (2015
179. Ma, C. X., et al. A phase I study of the AKT inhibitor MK 2206 in combination with hormonal therapy in postmenopausal women with estrogen receptor positive metastatic breast cancer. Clin. Cancer Res. http://dx.doi.org/10.1158/1078-0432.ccr-15-2160 (2016
180. Busaidy, N. L., et al. Management of metabolic effects associated with anticancer agents targeting the PI3K Akt-mTOR pathway. J. Clin. Oncol. 30, 2919-2928 (2012
181. Geuna, E., et al. Complications of hyperglycaemia with PI3K AKT-mTOR inhibitors in patients with advanced solid tumours on phase I clinical trials. Br. J. Cancer 113, 1541-1547 (2015
182. Gopal, A. K., et al. PI3Kd inhibition by idelalisib in patients with relapsed indolent lymphoma. N. Engl. J. Med. 370, 1008-1018 (2014
183. Iams, W. T., & Lovly, C. M. Molecular pathways: clinical applications and future direction of insulin-like growth factor 1 receptor pathway blockade. Clin. Cancer Res. 21, 4270-4277 (2015
184. Haluska, P., et al. Safety, tolerability, and pharmacokinetics of the anti-IGF 1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother. Pharmacol. 65, 765-773 (2010
185. Nellemann, B., et al. Growth hormone-induced insulin resistance in human subjects involves reduced pyruvate dehydrogenase activity. Acta Physiol. (Oxford) 210, 392-402 (2014
186. Yuen, K. C., Chong, L. E., & Riddle, M. C. Influence of glucocorticoids and growth hormone on insulin sensitivity in humans. Diabet. Med. 30, 651-663 (2013
187. Puzanov, I., et al. A phase I study of continuous oral dosing of OSI 906, a dual inhibitor of insulin-like growth factor 1 and insulin receptors, in patients with advanced solid tumors. Clin. Cancer Res. 21, 701-711 (2015
188. Rini, B. I., et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J. Clin. Oncol. 32, 752-759 (2014
189. Motzer, R. J., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803-1813 (2015
190. Yang, P., et al. Paradoxical effect of rapamycin on inflammatory stress-induced insulin resistance in vitro and in vivo. Sci. Rep. 5, 14959 (2015
191. Verges, B., & Cariou, B. mTOR inhibitors and diabetes. Diabetes Res. Clin. Pract. 110, 101-108 (2015
192. Baselga, J., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366, 520-529 (2012
193. Meacham, L. R., et al. Diabetes mellitus in long-Term survivors of childhood cancer. Increased risk associated with radiation therapy: a report for the childhood cancer survivor study. Arch. Intern. Med. 169, 1381-1388 (2009
194. Holmqvist, A. S., et al. Adult life after childhood cancer in Scandinavia: diabetes mellitus following treatment for cancer in childhood. Eur. J. Cancer 50, 1169-1175 (2014
195. van Nimwegen, F. A., et al. Risk of diabetes mellitus in long-Term survivors of Hodgkin lymphoma. J. Clin. Oncol. 32, 3257-3263 (2014
196. Ray, W. A. Evaluating medication effects outside of clinical trials: new-user designs. Am. J. Epidemiol. 158, 915-920 (2003
197. van Staa, T. P., Patel, D., Gallagher, A. M., & de Bruin, M. L. Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia 55, 654-665 (2012
198. Jones, N. P., Curtis, P. S., & Home, P. D. Cancer and bone fractures in observational follow up of the RECORD study. Acta Diabetol 52, 539-546 (2015
199. Wang, H., et al. NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. Sci. Transl. Med. 8, 334ra351 (2016
200. Devaraj, S., & Maitra, A. Pancreatic safety of newer incretin-based therapies: are the '-Tides' finally turning? Diabetes 63, 2219-2221 (2014
201. Bordeleau, L., et al. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care 37, 1360-1366 (2014